Valuation: Evotec SE

Market Cap 499M 571M 469M 428M 803M 54.56B 803M 5.63B 2.17B 27.86B 2.14B 2.1B 89.82B P/E 2026 *
-2.39x
P/E 2027 * -6.52x
Enterprise Value 642M 734M 603M 550M 1.03B 70.19B 1.03B 7.24B 2.79B 35.84B 2.76B 2.7B 116B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 0.91x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+2.60%
1 week-3.07%
Current month-15.96%
1 month-18.13%
3 months-39.69%
6 months-34.98%
Current year-48.70%
1 week 1.5
Extreme 1.5
1.75
1 month 1.5
Extreme 1.5
1.97
Current year 1.5
Extreme 1.5
3.87
1 year 1.5
Extreme 1.5
4.27
3 years 1.5
Extreme 1.5
12
5 years 1.5
Extreme 1.5
26.57
10 years 1.5
Extreme 1.5
26.57
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 59 2024-06-09
Change 5-day change 1-year change 3-year change Capi.($)
+2.60%-3.07% - - 570M
+2.55%+4.77%+4.07%+32.02% 46.68B
+0.08%+0.16%+43.79%+35.89% 44.42B
+0.05%-5.86%+334.27%+542.87% 41.32B
+0.66%+6.23%+8.96%+93.14% 41.58B
-1.60%-0.17%+9.73%+43.63% 30.14B
+0.96%+1.56%+26.52%+159.67% 17.42B
-0.01%-0.92% - - 15.6B
+1.15%+7.46%+25.97%+43.93% 15.54B
-1.08%+12.11%-10.11% - 14.08B
Average +0.57%+3.39%+55.40%+135.88% 29.64B
Weighted average by Cap. +0.48%+1.94%+69.02%+144.12%

Financials

2026 *2027 *
Net sales 601M 688M 565M 515M 967M 65.73B 967M 6.78B 2.62B 33.57B 2.58B 2.53B 108B 724M 829M 681M 621M 1.17B 79.21B 1.17B 8.17B 3.15B 40.45B 3.11B 3.04B 130B
Net income -202M -231M -190M -173M -325M -22.1B -325M -2.28B -879M -11.28B -868M -849M -36.38B -48.25M -55.21M -45.35M -41.38M -77.67M -5.28B -77.68M -544M -210M -2.7B -207M -203M -8.69B
Net Debt 143M 163M 134M 123M 230M 15.63B 230M 1.61B 622M 7.98B 614M 600M 25.73B 162M 186M 152M 139M 261M 17.74B 261M 1.83B 706M 9.06B 697M 682M 29.21B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
26-09-22 US$1.580 +2.60% 126,936
26-09-21 US$1.540 -3.75% 685,697
26-09-18 US$1.600 -4.19% 1,378,543
26-09-17 US$1.670 +2.45% 21,495
26-09-16 US$1.630 0.00% 24,916
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.806EUR
Average target price
4.586EUR
Spread / Average Target
+63.43%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!